Acrivon Therapeutics, Inc. SEC Filings

Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a non-derivative disposition on 10/01/2025. The filing shows 284 shares of common stock were disposed at a price of $1.81 per share. The form states the shares were withheld by the issuer to satisfy mandatory tax withholding upon the vesting of restricted stock units. After the reported transaction, Ms. Miller beneficially owns 35,297 shares, held directly. The Form 4 was signed by attorney-in-fact Adam D. Levy on 10/03/2025.

Acrivon Therapeutics, Inc. furnished a corporate presentation on its website, providing an update on its business and research programs. The presentation includes new syngeneic mouse model data showing continued strong synergy between its clinical candidates ACR-368 and ACR-2316 and immune checkpoint inhibitors. After multiple rounds of tumor implantation over almost one year, the models showed complete tumor regression and evidence of immune memory, and the company further analyzed which immune cell types drive this effect. These results support the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting. The company also updated its pipeline overview to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial and expanded information on its Generative Phosphoproteomics AP3 platform. The presentation is attached as Exhibit 99.1.

Acrivon Therapeutics insiders reported an internal share disposition related to restricted stock unit vesting. On 08/21/2025, President and CEO Dr. Peter Blume-Jensen had 19,905 common shares dispositioned at $1.32 per share; the filing states these shares were withheld by the issuer to satisfy mandatory tax withholding on vested restricted stock units. After the transaction Dr. Blume-Jensen is reported to beneficially own 2,126,440 shares (direct). The filing also shows 315,196 common shares held indirectly by EVP Dr. Kristina Masson. Both reporting persons are officers and directors and are spouses; each disclaims beneficial ownership of the other’s holdings except to the extent of pecuniary interest. The Form 4 is signed by an attorney-in-fact on behalf of both reporting persons.

Acrivon Therapeutics insider sale reported on Form 4. Katharine Peterson, Chief Accounting Officer, recorded a transaction dated 08/14/2025 disclosing a disposition of 99 shares of Acrivon Therapeutics common stock at a price of $1.39 per share. Following the reported sale, Ms. Peterson beneficially owns 4,221 shares, held directly. The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting and is signed by an attorney-in-fact on 08/18/2025.

Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on 08/14/2025 involving the company’s common stock. The filing shows 184 shares were disposed at a price of $1.39 per share.

The form states these shares were withheld by the issuer to satisfy a mandatory tax withholding obligation upon the vesting of restricted stock units. After the withholding, Ms. Miller beneficially owns 35,581 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reported a routine withholding of 403 shares of Common Stock on 08/14/2025 to satisfy mandatory tax withholding when restricted stock units vested. The withheld shares were disposed at a reported price of $1.39 per share. After the transaction, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to cover taxes tied to RSU vesting.

Acrivon Therapeutics insider transaction summary: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reported a single Form 4 transaction. On 08/14/2025 the reporting person had 613 shares withheld at a price of $1.39 per share as a result of tax withholding tied to the vesting of restricted stock units. After this withholding disposition, the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to satisfy mandatory tax obligations and includes a Power of Attorney exhibit.

Acrivon Therapeutics insiders reported routine post-vesting share dispositions on 08/14/2025. The Form 4 shows that restricted stock units were treated by the issuer to cover mandatory tax withholding: 59,766 shares were withheld at an effective price of $1.39, recorded as a disposition. After that transaction, Peter Blume-Jensen is shown as beneficially owning 2,146,345 shares (direct) and 315,196 shares (indirect) attributable to spouse holdings. A separate small disposition of 490 shares at $1.39 is reported as indirect ownership. Both Dr. Blume-Jensen (President and CEO) and Dr. Kristina Masson (EVP, Business Operations) are listed as reporting persons and each signed via attorney-in-fact on 08/18/2025.